AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Tandem Diabetes Care, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

SEC Form 4 filed on 06/18/2025 reveals that Tandem Diabetes Care, Inc. (TNDM) director Myoungil Cha acquired 1,749 shares of common stock on 06/16/2025 through the vesting and settlement of previously granted restricted stock units (RSUs) under the company’s 2013 Stock Incentive Plan. The conversion, reported with transaction code “M,â€� was executed at $0 cost to the insider and involved no open-market purchase or sale.

Following the transaction, Cha’s direct beneficial ownership rose from 11,950 to 13,699 shares. The RSU grant was originally awarded on 06/15/2022 and vests in three equal annual installments; the reported shares represent the second installment, with additional tranches scheduled for future anniversaries, subject to plan terms.

Key takeaways:

  • Insider ownership increase: +1,749 shares, signalling continued alignment with shareholder interests.
  • Routine equity compensation: Transaction stems from standard RSU vesting, not discretionary market activity.
  • No cash proceeds or sales: Neutral impact on near-term share flow and insider liquidity.

Il modulo SEC Form 4 presentato il 18/06/2025 rivela che il direttore di Tandem Diabetes Care, Inc. (TNDM), Myoungil Cha, ha acquisito 1.749 azioni ordinarie il 16/06/2025 tramite la maturazione e liquidazione di unità azionarie vincolate (RSU) precedentemente assegnate nell'ambito del Piano di Incentivi Azionari 2013 della società. La conversione, segnalata con il codice transazione “M,� è stata effettuata a costo zero per l'insider e non ha coinvolto acquisti o vendite sul mercato aperto.

Dopo la transazione, la proprietà diretta di Cha è aumentata da 11.950 a 13.699 azioni. La concessione delle RSU è stata originariamente assegnata il 15/06/2022 e si matura in tre rate annuali uguali; le azioni riportate rappresentano la seconda rata, con ulteriori tranche previste per i prossimi anniversari, soggette ai termini del piano.

Punti chiave:

  • Aumento della proprietà insider: +1.749 azioni, segnale di un continuo allineamento con gli interessi degli azionisti.
  • Compenso azionario di routine: La transazione deriva dalla maturazione standard delle RSU, non da attività discrezionali di mercato.
  • Nessun ricavo in contanti o vendita: Impatto neutro sul flusso azionario a breve termine e sulla liquidità dell'insider.

El formulario SEC Form 4 presentado el 18/06/2025 revela que el director de Tandem Diabetes Care, Inc. (TNDM), Myoungil Cha, adquirió 1,749 acciones ordinarias el 16/06/2025 mediante la consolidación y liquidación de unidades de acciones restringidas (RSU) previamente otorgadas bajo el Plan de Incentivos de Acciones 2013 de la compañía. La conversión, reportada con el código de transacción “M,� se realizó sin costo ($0) para el insider y no involucró compras o ventas en el mercado abierto.

Tras la transacción, la propiedad directa de Cha aumentó de 11,950 a 13,699 acciones. La concesión de RSU fue originalmente otorgada el 15/06/2022 y se consolida en tres cuotas anuales iguales; las acciones reportadas corresponden a la segunda cuota, con tramos adicionales previstos para futuros aniversarios, sujetos a los términos del plan.

Puntos clave:

  • Aumento en la propiedad del insider: +1,749 acciones, indicando un alineamiento continuo con los intereses de los accionistas.
  • Compensación accionaria rutinaria: La transacción proviene de la consolidación estándar de RSU, no de actividad discrecional en el mercado.
  • Sin ingresos en efectivo ni ventas: Impacto neutral en el flujo de acciones a corto plazo y en la liquidez del insider.

2025ë…� 6ì›� 18ì� 제출ë� SEC Form 4ì—� 따르ë©� Tandem Diabetes Care, Inc.(TNDM) ì´ì‚¬ Myoungil Chaê°€ 2025ë…� 6ì›� 16ì� 회사ì� 2013ë…� ì£¼ì‹ ì¸ì„¼í‹°ë¸Œ 계íšì—� ë”°ë¼ ì´ì „ì—� ë¶€ì—¬ëœ ì œí•œ ì£¼ì‹ ë‹¨ìœ„(RSU)ì� 권리 확정 ë°� ì •ì‚°ì� 통해 1,749ì£�ì� 보통주를 ì·¨ë“했습니다. 거래 코드ëŠ� “Mâ€ìœ¼ë¡� ë³´ê³ ë˜ì—ˆìœ¼ë©°, ë‚´ë¶€ìžì—게는 0달러 비용ì� ë°œìƒí–ˆìœ¼ë©�, 공개 시장ì—서ì� 매수ë‚� 매ë„ëŠ� 없었습니ë‹�.

ì� 거래 í›� Chaì� ì§ì ‘ 소유 ì£¼ì‹ ìˆ˜ëŠ” 11,950주ì—ì„� 13,699ì£�ë¡� ì¦ê°€í–ˆìŠµë‹ˆë‹¤. RSU 부여는 2022ë…� 6ì›� 15ì¼ì— ì²˜ìŒ ì´ë£¨ì–´ì¡Œìœ¼ë©° 3ë…„ê°„ 매년 ë™ì¼í•� 비율ë¡� 권리가 확정ë©ë‹ˆë‹�; ë³´ê³ ë� 주ì‹ì€ ë‘� 번째 ë¶„í• ë¶„ì´ë©�, 향후 기ë…ì¼ì— 추가 ë¶„í• ë¶„ì´ ì˜ˆì •ë˜ì–´ 있으ë©� ê³„íš ì¡°ê±´ì—� 따릅니다.

주요 내용:

  • ë‚´ë¶€ìž� 소유ê¶� ì¦ê°€: +1,749ì£�, 주주 ì´ìµê³¼ì˜ ì§€ì†ì ì� ì¼ì¹˜ë¥� 나타ëƒ�.
  • ì¼ìƒì ì¸ ì£¼ì‹ ë³´ìƒ: 거래ëŠ� 표준 RSU 권리 확정ì—서 비롯ë˜ì—ˆìœ¼ë©°, ìž„ì˜ ì‹œìž¥ 활ë™ì� 아님.
  • 현금 ìˆ˜ìµ ë˜ëŠ” ë§¤ë„ ì—†ìŒ: 단기 ì£¼ì‹ ìœ í†µ ë°� ë‚´ë¶€ìž� 유ë™ì„±ì— 중립ì � ì˜í–¥.

Le formulaire SEC Form 4 déposé le 18/06/2025 révèle que le directeur de Tandem Diabetes Care, Inc. (TNDM), Myoungil Cha, a acquis 1 749 actions ordinaires le 16/06/2025 via l'acquisition et le règlement d'unités d'actions restreintes (RSU) précédemment attribuées dans le cadre du Plan d'Incitation en Actions de 2013 de la société. La conversion, rapportée avec le code de transaction « M », a été réalisée à un coût de 0 $ pour l'initié et n'a impliqué aucun achat ou vente sur le marché ouvert.

Suite à la transaction, la propriété directe de Cha est passée de 11 950 à 13 699 actions. L'attribution des RSU a été initialement effectuée le 15/06/2022 et se libère en trois versements annuels égaux ; les actions rapportées représentent la deuxième tranche, avec d'autres tranches prévues pour les anniversaires futurs, sous réserve des conditions du plan.

Points clés :

  • Augmentation de la détention d'initiés : +1 749 actions, signalant un alignement continu avec les intérêts des actionnaires.
  • Rémunération en actions de routine : La transaction découle de la libération standard des RSU, non d'une activité discrétionnaire sur le marché.
  • Pas de produit en espèces ni de vente : Impact neutre sur le flux d'actions à court terme et la liquidité de l'initié.

Das am 18.06.2025 eingereichte SEC Formular 4 zeigt, dass Tandem Diabetes Care, Inc. (TNDM) Direktor Myoungil Cha am 16.06.2025 1.749 Aktien des Stammkapitals durch die Ausübung und Abwicklung zuvor gewährter Restricted Stock Units (RSUs) im Rahmen des Aktienanreizplans von 2013 erworben hat. Die Umwandlung, gemeldet mit dem Transaktionscode „M�, erfolgte für den Insider kostenfrei (0 $) und beinhaltete keinen Kauf oder Verkauf am offenen Markt.

Nach der Transaktion stieg Chas direkte Beteiligung von 11.950 auf 13.699 Aktien. Die RSU-Zuteilung wurde ursprünglich am 15.06.2022 gewährt und wird in drei gleichen jährlichen Raten fällig; die gemeldeten Aktien stellen die zweite Rate dar, weitere Tranchen sind für zukünftige Jahrestage vorgesehen, vorbehaltlich der Planbedingungen.

Wesentliche Erkenntnisse:

  • Erhöhung der Insider-Beteiligung: +1.749 Aktien, was auf eine weiterhin enge Ausrichtung an den Interessen der Aktionäre hinweist.
  • Routinemäßige Aktienvergütung: Die Transaktion resultiert aus der regulären RSU-Fälligkeit, nicht aus diskretionären Marktaktivitäten.
  • Keine Barausschüttungen oder Verkäufe: Neutraler Einfluss auf den kurzfristigen Aktienfluss und die Liquidität des Insiders.
Positive
  • Insider ownership increased by 1,749 shares, suggesting continued equity alignment with shareholders.
Negative
  • None.

Insights

TL;DR â€� Routine RSU vesting adds 1,749 shares to director’s holdings; market impact minimal.

The filing shows an automatic conversion of RSUs, increasing Cha’s stake to 13,699 shares. Because no shares were sold and the exercise price was $0, the transaction is non-dilutive beyond the ordinary course of equity compensation. Such activity is typical for directors and is unlikely to alter near-term supply-demand dynamics or valuation multiples. Investors may view the retention of shares as a mild positive signal, but the size—well below 1% of float—keeps overall impact neutral.

TL;DR â€� Standard plan-based vesting; supports alignment but not materially significant.

This Form 4 reflects compliance with Tandem Diabetes Care’s 2013 Stock Incentive Plan. The director did not elect a 10b5-1 sale program and retained the newly issued shares, which can be interpreted as confidence in the firm. However, without additional buying or sizeable ownership changes, governance implications remain neutral. No red flags regarding timing or disclosure are evident.

Il modulo SEC Form 4 presentato il 18/06/2025 rivela che il direttore di Tandem Diabetes Care, Inc. (TNDM), Myoungil Cha, ha acquisito 1.749 azioni ordinarie il 16/06/2025 tramite la maturazione e liquidazione di unità azionarie vincolate (RSU) precedentemente assegnate nell'ambito del Piano di Incentivi Azionari 2013 della società. La conversione, segnalata con il codice transazione “M,� è stata effettuata a costo zero per l'insider e non ha coinvolto acquisti o vendite sul mercato aperto.

Dopo la transazione, la proprietà diretta di Cha è aumentata da 11.950 a 13.699 azioni. La concessione delle RSU è stata originariamente assegnata il 15/06/2022 e si matura in tre rate annuali uguali; le azioni riportate rappresentano la seconda rata, con ulteriori tranche previste per i prossimi anniversari, soggette ai termini del piano.

Punti chiave:

  • Aumento della proprietà insider: +1.749 azioni, segnale di un continuo allineamento con gli interessi degli azionisti.
  • Compenso azionario di routine: La transazione deriva dalla maturazione standard delle RSU, non da attività discrezionali di mercato.
  • Nessun ricavo in contanti o vendita: Impatto neutro sul flusso azionario a breve termine e sulla liquidità dell'insider.

El formulario SEC Form 4 presentado el 18/06/2025 revela que el director de Tandem Diabetes Care, Inc. (TNDM), Myoungil Cha, adquirió 1,749 acciones ordinarias el 16/06/2025 mediante la consolidación y liquidación de unidades de acciones restringidas (RSU) previamente otorgadas bajo el Plan de Incentivos de Acciones 2013 de la compañía. La conversión, reportada con el código de transacción “M,� se realizó sin costo ($0) para el insider y no involucró compras o ventas en el mercado abierto.

Tras la transacción, la propiedad directa de Cha aumentó de 11,950 a 13,699 acciones. La concesión de RSU fue originalmente otorgada el 15/06/2022 y se consolida en tres cuotas anuales iguales; las acciones reportadas corresponden a la segunda cuota, con tramos adicionales previstos para futuros aniversarios, sujetos a los términos del plan.

Puntos clave:

  • Aumento en la propiedad del insider: +1,749 acciones, indicando un alineamiento continuo con los intereses de los accionistas.
  • Compensación accionaria rutinaria: La transacción proviene de la consolidación estándar de RSU, no de actividad discrecional en el mercado.
  • Sin ingresos en efectivo ni ventas: Impacto neutral en el flujo de acciones a corto plazo y en la liquidez del insider.

2025ë…� 6ì›� 18ì� 제출ë� SEC Form 4ì—� 따르ë©� Tandem Diabetes Care, Inc.(TNDM) ì´ì‚¬ Myoungil Chaê°€ 2025ë…� 6ì›� 16ì� 회사ì� 2013ë…� ì£¼ì‹ ì¸ì„¼í‹°ë¸Œ 계íšì—� ë”°ë¼ ì´ì „ì—� ë¶€ì—¬ëœ ì œí•œ ì£¼ì‹ ë‹¨ìœ„(RSU)ì� 권리 확정 ë°� ì •ì‚°ì� 통해 1,749ì£�ì� 보통주를 ì·¨ë“했습니다. 거래 코드ëŠ� “Mâ€ìœ¼ë¡� ë³´ê³ ë˜ì—ˆìœ¼ë©°, ë‚´ë¶€ìžì—게는 0달러 비용ì� ë°œìƒí–ˆìœ¼ë©�, 공개 시장ì—서ì� 매수ë‚� 매ë„ëŠ� 없었습니ë‹�.

ì� 거래 í›� Chaì� ì§ì ‘ 소유 ì£¼ì‹ ìˆ˜ëŠ” 11,950주ì—ì„� 13,699ì£�ë¡� ì¦ê°€í–ˆìŠµë‹ˆë‹¤. RSU 부여는 2022ë…� 6ì›� 15ì¼ì— ì²˜ìŒ ì´ë£¨ì–´ì¡Œìœ¼ë©° 3ë…„ê°„ 매년 ë™ì¼í•� 비율ë¡� 권리가 확정ë©ë‹ˆë‹�; ë³´ê³ ë� 주ì‹ì€ ë‘� 번째 ë¶„í• ë¶„ì´ë©�, 향후 기ë…ì¼ì— 추가 ë¶„í• ë¶„ì´ ì˜ˆì •ë˜ì–´ 있으ë©� ê³„íš ì¡°ê±´ì—� 따릅니다.

주요 내용:

  • ë‚´ë¶€ìž� 소유ê¶� ì¦ê°€: +1,749ì£�, 주주 ì´ìµê³¼ì˜ ì§€ì†ì ì� ì¼ì¹˜ë¥� 나타ëƒ�.
  • ì¼ìƒì ì¸ ì£¼ì‹ ë³´ìƒ: 거래ëŠ� 표준 RSU 권리 확정ì—서 비롯ë˜ì—ˆìœ¼ë©°, ìž„ì˜ ì‹œìž¥ 활ë™ì� 아님.
  • 현금 ìˆ˜ìµ ë˜ëŠ” ë§¤ë„ ì—†ìŒ: 단기 ì£¼ì‹ ìœ í†µ ë°� ë‚´ë¶€ìž� 유ë™ì„±ì— 중립ì � ì˜í–¥.

Le formulaire SEC Form 4 déposé le 18/06/2025 révèle que le directeur de Tandem Diabetes Care, Inc. (TNDM), Myoungil Cha, a acquis 1 749 actions ordinaires le 16/06/2025 via l'acquisition et le règlement d'unités d'actions restreintes (RSU) précédemment attribuées dans le cadre du Plan d'Incitation en Actions de 2013 de la société. La conversion, rapportée avec le code de transaction « M », a été réalisée à un coût de 0 $ pour l'initié et n'a impliqué aucun achat ou vente sur le marché ouvert.

Suite à la transaction, la propriété directe de Cha est passée de 11 950 à 13 699 actions. L'attribution des RSU a été initialement effectuée le 15/06/2022 et se libère en trois versements annuels égaux ; les actions rapportées représentent la deuxième tranche, avec d'autres tranches prévues pour les anniversaires futurs, sous réserve des conditions du plan.

Points clés :

  • Augmentation de la détention d'initiés : +1 749 actions, signalant un alignement continu avec les intérêts des actionnaires.
  • Rémunération en actions de routine : La transaction découle de la libération standard des RSU, non d'une activité discrétionnaire sur le marché.
  • Pas de produit en espèces ni de vente : Impact neutre sur le flux d'actions à court terme et la liquidité de l'initié.

Das am 18.06.2025 eingereichte SEC Formular 4 zeigt, dass Tandem Diabetes Care, Inc. (TNDM) Direktor Myoungil Cha am 16.06.2025 1.749 Aktien des Stammkapitals durch die Ausübung und Abwicklung zuvor gewährter Restricted Stock Units (RSUs) im Rahmen des Aktienanreizplans von 2013 erworben hat. Die Umwandlung, gemeldet mit dem Transaktionscode „M�, erfolgte für den Insider kostenfrei (0 $) und beinhaltete keinen Kauf oder Verkauf am offenen Markt.

Nach der Transaktion stieg Chas direkte Beteiligung von 11.950 auf 13.699 Aktien. Die RSU-Zuteilung wurde ursprünglich am 15.06.2022 gewährt und wird in drei gleichen jährlichen Raten fällig; die gemeldeten Aktien stellen die zweite Rate dar, weitere Tranchen sind für zukünftige Jahrestage vorgesehen, vorbehaltlich der Planbedingungen.

Wesentliche Erkenntnisse:

  • Erhöhung der Insider-Beteiligung: +1.749 Aktien, was auf eine weiterhin enge Ausrichtung an den Interessen der Aktionäre hinweist.
  • Routinemäßige Aktienvergütung: Die Transaktion resultiert aus der regulären RSU-Fälligkeit, nicht aus diskretionären Marktaktivitäten.
  • Keine Barausschüttungen oder Verkäufe: Neutraler Einfluss auf den kurzfristigen Aktienfluss und die Liquidität des Insiders.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cha Myoungil

(Last) (First) (Middle)
12400 HIGH BLUFF DRIVE

(Street)
SAN DIEGO CA 92130

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
TANDEM DIABETES CARE INC [ TNDM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/16/2025 M 1,749 A $0 13,699 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit(1) (2) 06/16/2025 M 1,749 (3) (3) Common Stock 1,749 $0 0 D
Explanation of Responses:
1. Awarded on June 15, 2022 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan).
2. Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.
3. The total number of shares subject to the RSU will vest over a period of three years in equal annual installments on the anniversary of the grant, subject to the terms of the 2013 Plan.
Remarks:
/s/ Rachel Malina, Attorney-in-Fact for Myoungil Cha 06/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Tandem Diabetes Care (TNDM) report on 06/18/2025?

Director Myoungil Cha converted 1,749 RSUs into common stock, classified as code “M.�

How many TNDM shares does Myoungil Cha own after the transaction?

Cha now directly owns 13,699 shares of Tandem Diabetes Care common stock.

Did the insider sell any Tandem Diabetes Care shares?

No. The filing shows an RSU conversion with no shares sold and no cash proceeds.

What does transaction code “M� indicate in a Form 4?

Code “M� denotes the conversion of derivative securities, such as RSUs, into common stock.

When were the RSUs originally granted?

The RSUs were awarded on June 15, 2022 under the 2013 Stock Incentive Plan.

What is the vesting schedule for these RSUs?

The RSUs vest in three equal annual installments on each anniversary of the grant date.
Tandem Diabetes

NASDAQ:TNDM

TNDM Rankings

TNDM Latest News

TNDM Latest SEC Filings

TNDM Stock Data

1.01B
65.92M
0.95%
111.43%
15.16%
Medical Devices
Surgical & Medical Instruments & Apparatus
United States
San Diego